TCA/GENETWORx Labs has unveiled a diagnostic Flu A-B/COVID-19/RSV combination test that provides patients with early detection of all three separate respiratory viruses with just one test sample.

The TCA/GENETWORx Flu A-B/COVID Combo Test is a molecular diagnostic PCR test that detects two types of influenza viruses—influenza A and B—and differentiates them from RSV, and SARS-CoV-2, the virus that causes COVID-19. The Flu A-B/COVID Combo Test provided by GENETWORx has a 98% accuracy rate for influenza, 99% for COVID-19, and 96% for RSV.

The capability to test for influenza A/B, RSV, and COVID-19 from a single mid-turbinate or nasopharyngeal swab sample means less discomfort for patients than collecting a separate sample each test. Testing a single sample for several pathogens uses fewer resources and takes less time than running several individual tests on multiple samples to detect different pathogens.

Test results for the new TCA/GENETWORx Combo test will be available in 48 hours. GENETWORx also has one of the fastest results-reporting platforms where patients or providers can easily access test results in an online portal and via text or phone, or through the comprehensive COVID-19 software solution, named Aura.  

Aura software users have expedited turnaround times for the Flu A-B/COVID Combo Test and other GENETWORx COVID-19 tests. The end-to-end digital management system also significantly reduces laboratory process time and helps ensure a compliant, safe, healthy population for healthcare providers, schools, universities, governments, cities, employers, and others.

Moreover, the Aura platform provides user-friendly assistance with all facets needed for comprehensive sequential testing. Aura helps users find and schedule testing, including sending reminders, symptom tracking, identification of compliance using QR bar codes, and contact tracing assistance.  

An approval date for a COVID-19 vaccine is still yet to be determined, and the flu vaccine is dependent on which strain of influenza is circulating each year. There is currently no vaccine for RSV. Even with the correct strain, the flu vaccine is not 100% reliable. With all the unknowns and risks associated with this upcoming flu and RSV season, the new TCA/GENETWORx test is an important advancement in diagnostic medicine during the pandemic.

GENETWORx is a fully integrated CAP/CLIA certified high complexity molecular diagnostic laboratory. In addition to COVID-19 testing, the company also provides pharmacogenomic DNA genotyping.  

For more details, please use the 'Request Information' button provided below.